|  |
| --- |
| **Supplemental Table 1.** **Descriptive characteristics of cases who completed baseline and follow-up surveys** |
|  | **Cases without follow-up survey**n=274 | **Cases with follow-up survey**n=264 |  |
|  | **n** | **(%)** | **n** | **(%)** | **p-value**a |
| **Mean age at diagnosis (years) (SD)** | 57.0 | (11.1) | 58.0 | (10.3) | 0.21 |
| **Median age at diagnosis (years)** | 57.0 |  | 57.0 |  |  |
| **Region** |  |  |  |  | 0.91 |
|  South- and mid-Atlantic | 156 | (56.9) | 149 | (56.4) |  |
|  South central | 82 | (29.9) | 77 | (29.2) |  |
|  Midwest | 36 | (13.1) | 38 | (14.4) |  |
| **Education** |  |  |  |  | 0.97 |
|  High school or less | 121 | (44.2) | 117 | (44.3) |  |
|  Some post-high school training | 71 | (25.9) | 66 | (25.0) |  |
|  College or graduate degree | 82 | (29.9) | 81 | (30.7) |  |
| **Family Income** |  |  |  |  | 0.58 |
|  <$25,000 | 128 | (46.7) | 117 | (44.3) |  |
|  >$25,000 | 146 | (53.3) | 147 | (55.7) |  |
| **Number of comorbid conditions**b |  |  |  |  | 0.57 |
|  0 | 95 | (34.7) | 102 | (38.6) |  |
|  1 | 61 | (22.3) | 59 | (22.4) |  |
|  2+ | 118 | (43.1) | 103 | (39.0) |  |
| **BMI**a **(kg/m2) at baseline** |  |  |  |  | 0.78 |
|  <25 (under- or normal weight) | 38 | (13.9) | 42 | (15.9) |  |
|  25-29.9 (overweight) | 72 | (26.3) | 70 | (26.5) |  |
|  30+ (obese) | 164 | (59.9) | 152 | (57.6) |  |
| **Parity (number of live births)** |  |  |  |  | 0.65 |
|  0 | 54 | (19.7) | 50 | (18.9) |  |
|  1 | 53 | (19.3) | 41 | (15.5) |  |
|  2 | 62 | (22.6) | 66 | (25.0) |  |
|  3+ | 105 | (38.3) | 107 | (40.5) |  |
| **Family history of breast or ovarian cancer** |  |  |  |  | 0.51 |
|  No | 202 | (73.7) | 188 | (71.2) |  |
|  Yes | 72 | (26.3) | 76 | (28.8) |  |
| **Menopausal status** |  |  |  |  | 0.48 |
|  Premenopausal | 78 | (28.5) | 68 | (25.8) |  |
|  Postmenopausal | 196 | (71.5) | 196 | (74.2) |  |
| **Smoking status** |  |  |  |  | 0.21 |
|  Never | 143 | (52.2) | 152 | (57.6) |  |
|  Ever | 131 | (47.8) | 112 | (42.4) |  |
| **Occupational physical activity** |  |  |  |  |  |
|  Mainly sitting | 54 | (19.7) | 45 | (17.1) | 0.07 |
|  Mainly standing or walking | 34 | (12.4) | 55 | (20.8) |  |
|  Mainly active | 47 | (17.2) | 42 | (15.9) |  |
|  Do not work outside the home | 139 | (50.7) | 122 | (46.2) |  |
| **Stage** |  |  |  |  | 0.03 |
|  I-II | 80 | (29.2) | 94 | (35.6) |  |
|  III-IV | 168 | (61.3) | 159 | (60.2) |  |
|  Unstaged | 26 | (9.5) | 11 | (4.2) |  |
| **Histology** |  |  |  |  | 0.69 |
|  Serous | 184 | (67.2) | 182 | (68.9) |  |
|  Mucinous | 19 | (6.9) | 10 | (3.8) |  |
|  Endometrioid | 28 | (10.2) | 37 | (14.0) |  |
|  Clear cell | 5 | (1.8) | 11 | (4.2) |  |
|  Other | 21 | (7.7) | 20 | (7.6) |  |
|  Missing | 17 | (6.2) | 4 | (1.5) |  |
| **Residual disease** |  |  |  |  | 0.14 |
|  Optimal debulking | 91 | (33.2) | 113 | (42.8) |  |
|  Suboptimal debulking | 52 | (19.0) | 45 | (17.1) |  |
|  NA – no surgery | 7 | (2.6) | 0 | (0.0) |  |
|  Missing residual disease | 124 | (45.3) | 106 | (40.2) |  |
| **Chemotherapy** |  |  |  |  |  |
|  No | 8 | (2.9) | 20 | (7.6) | 0.07 |
|  Yes | 168 | (61.3) | 193 | (73.1) |  |
|  Unknown | 98 | (35.8) | 51 | (19.3) |  |
| a P-value for difference between cases with and without a follow-up surveyb Number of comorbid conditions was determined using a modified Charlson comorbidity index1 |